Molecular determinants of anti-RBC alloantibody evanescence
抗红细胞同种抗体消失的分子决定因素
基本信息
- 批准号:10687424
- 负责人:
- 金额:$ 79.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-13 至 2023-10-31
- 项目状态:已结题
- 来源:
- 关键词:AffinityAllogenicAlloimmunizationAntibodiesAntibody AffinityAntibody FormationAntibody ResponseAntigen PresentationAntigen-Presenting CellsAntigensApoptoticAutomobile DrivingB cell differentiationB-LymphocytesBiological Response ModifiersBloodBlood BanksCD4 Positive T LymphocytesCell Differentiation processCellsCessation of lifeChronicChronic CareClinicalComplicationCoupledDataDendritic CellsDendritic cell activationDependenceDetectionDevelopmentDiagnosticDropsErythrocyte TransfusionErythrocytesEventFutureGenerationsHelper-Inducer T-LymphocyteImmuneImmune responseImmunoglobulin Somatic HypermutationInflammatoryInjuryInnate Immune ResponseInnate Immune SystemInterleukin-10Interleukin-4IsoantibodiesLeadLifeLipidsMalariaModelingMolecularMolecular TargetMorbidity - disease ratePatientsPhenotypePlasma CellsPlasmablastPlatelet Activating FactorProcessProductionPublishingReactionRiskSerineSickle Cell AnemiaSignal TransductionStructure of germinal center of lymph nodeT-LymphocyteTNFSF4 geneTestingTherapeuticTherapeutic InterventionTimeTransfusionVaccinationVirus Diseasesclinical developmentdifferential expressionfallshazardhigh riskmalaria infectionmortalitymouse modelnovelnovel therapeutic interventionpatient responseresponsetherapeutically effective
项目摘要
Summary. For patients who require chronic transfusion, the generation of antibodies to red blood cell (RBC)
antigens can be a major clinical problem. Anti-RBC antibodies often make finding compatible blood difficult
for these patients, which is particularly unfortunate since these RBC transfusions are often lifesaving. A major
complication arises when these anti-RBC alloantibodies disappear before detection in the blood bank, a
process referred to as evanescence. Patients whose antibodies have disappeared can unknowingly receive
a second transfusion of incompatible blood. This incompatible transfusion can induce a life-threatening event
called delayed hemolytic transfusion reaction. Anti-RBC evanescence therefore directly leads to delayed
hemolytic transfusion reactions, which are a major cause of injury and death in chronically transfused patients.
This is a particularly serious problem for patients with sickle cell disease, who often require frequent
transfusions and have high rates of evanescent antibodies. Despite its clinical importance, the molecular
factors that lead to anti-RBC alloantibody evanescence are completely unknown. Accordingly, there are no
effective therapeutic interventions available to alloimmunized patients other than antigen avoidance. We have
recently made the novel finding that the HOD mouse model of red blood cell (RBC) alloimmunization
recapitulates many of the key clinical features seen in chronically transfused patients. Specifically, we have
shown that HOD RBC transfusion leads to the preferential generation of low-affinity, rapidly evanescent anti-
RBC alloantibodies at the expense of high-affinity, persistent antibodies. Herein we propose to use this mouse
model to investigate why RBC transfusion leads to rapidly evanescent antibodies rather than long-lived ones.
Our central hypothesis is that RBC presentation of antigens directly alters the innate immune responses of
recipients, driving the differentiation of CD4+ T cells into helper cells which are unable to sustain long-lived
interactions with B cells. We hypothesize that though these T cells can drive extrafollicular antibody responses
that produce low-affinity, short-lived antibodies, they are blocked in their ability to drive germinal center
responses that allow for somatic hypermutation, antibody affinity maturation, and long-lived antibody
producing plasma cells. By better understanding how the fundamental cellular and molecular immune
regulators of anti-RBC alloantibodies are regulated over time, we hope to discover novel molecular targets
that can serve as potential future therapeutics for those patients who are at high risk from the complications
of RBC alloimmunization.
总结。对于需要长期输血的患者,红细胞抗体的产生
抗原可能是一个主要的临床问题。抗RBC抗体经常使寻找相容血液变得困难
对于这些患者来说,这特别不幸,因为这些红细胞输注通常是挽救生命的。一位少校
当这些抗红细胞同种异体抗体在血库中检测到之前消失时,就会出现并发症。
这一过程被称为消逝。抗体消失的患者可能在不知不觉中收到
第二次输不相容的血。这种不相容的输血可能会引发危及生命的事件
称为延迟溶血性输血反应。因此,抗红细胞消逝直接导致延迟
溶血性输血反应,这是慢性输血患者受伤和死亡的主要原因。
对于患有镰状细胞病的患者来说,这是一个特别严重的问题,他们经常需要
输血并有很高的抗体消失率。尽管它具有临床重要性,但分子
导致抗RBC同种异体抗体消失的因素是完全未知的。因此,没有
对异体免疫的患者可采取有效的治疗干预措施,而不是避免抗原。我们有
最近新近发现HOD小鼠模型对红细胞(RBC)的同种免疫
总结了许多在慢性输血患者中看到的关键临床特征。具体来说,我们有
结果表明,HOD红细胞输注可优先产生低亲和力、快速消逝的抗-HBc。
红细胞同种异体抗体以高亲和力、持久性抗体为代价。在这里,我们建议使用这个鼠标
模型来研究为什么输血红细胞会导致快速消逝的抗体,而不是长寿的抗体。
我们的中心假设是,红细胞呈递抗原直接改变先天免疫反应。
受体,推动CD4+T细胞分化为无法长期生存的辅助细胞
与B细胞的相互作用。我们推测,尽管这些T细胞可以驱动卵泡外抗体反应
产生低亲和力、短命抗体,它们驱动生发中心的能力受阻
允许体细胞高度突变、抗体亲和力成熟和抗体长寿的反应
产生浆细胞。通过更好地了解基础细胞和分子免疫是如何
抗RBC同种异体抗体的调节是随着时间的推移而调节的,我们希望发现新的分子靶点
这可以作为未来潜在的治疗方法,用于那些有高并发症风险的患者。
红细胞同种异体免疫。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CHANCE MARION JOHN LUCKEY其他文献
CHANCE MARION JOHN LUCKEY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CHANCE MARION JOHN LUCKEY', 18)}}的其他基金
Basic and Translational Mechanisms of Alloimmunization to RBC Transfusion. Project 2
红细胞输注同种免疫的基本和转化机制。
- 批准号:
10711669 - 财政年份:2023
- 资助金额:
$ 79.83万 - 项目类别:
Cellular and Molecular Determinants of RBC Alloimmunization Responder Status
红细胞同种免疫应答状态的细胞和分子决定因素
- 批准号:
10192795 - 财政年份:2017
- 资助金额:
$ 79.83万 - 项目类别:
Cyokine control of red blood cell alloimmunization
红细胞同种免疫的细胞因子控制
- 批准号:
9214994 - 财政年份:2016
- 资助金额:
$ 79.83万 - 项目类别:
Transcriptional Control of Memory Responses to Red Blood Cell Alloimmunization
红细胞同种免疫记忆反应的转录控制
- 批准号:
9017157 - 财政年份:2014
- 资助金额:
$ 79.83万 - 项目类别:
Transcriptional Control of Memory Responses to Red Blood Cell Alloimmunization
红细胞同种免疫记忆反应的转录控制
- 批准号:
8567036 - 财政年份:2013
- 资助金额:
$ 79.83万 - 项目类别:
Transcriptional Control of Memory Responses to Red Blood Cell Alloimmunization
红细胞同种免疫记忆反应的转录控制
- 批准号:
8703785 - 财政年份:2013
- 资助金额:
$ 79.83万 - 项目类别:
Cytokine control of Red Blood Cell Alloimmunization
红细胞同种免疫的细胞因子控制
- 批准号:
8228956 - 财政年份:2012
- 资助金额:
$ 79.83万 - 项目类别:
Cytokine control of Red Blood Cell Alloimmunization
红细胞同种免疫的细胞因子控制
- 批准号:
8424288 - 财政年份:2012
- 资助金额:
$ 79.83万 - 项目类别:
Pou6f1 transcriptional control of memory CD8+ T cells
Pou6f1 记忆 CD8 T 细胞的转录控制
- 批准号:
8164939 - 财政年份:2011
- 资助金额:
$ 79.83万 - 项目类别:
Pou6f1 transcriptional control of memory CD8+ T cells
Pou6f1 记忆 CD8 T 细胞的转录控制
- 批准号:
8264746 - 财政年份:2011
- 资助金额:
$ 79.83万 - 项目类别:
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 79.83万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 79.83万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 79.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 79.83万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 79.83万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 79.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 79.83万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 79.83万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 79.83万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 79.83万 - 项目类别:
Grant-in-Aid for Scientific Research (B)